These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9830012)

  • 1. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
    Kalman K; Pennington MW; Lanigan MD; Nguyen A; Rauer H; Mahnir V; Paschetto K; Kem WR; Grissmer S; Gutman GA; Christian EP; Cahalan MD; Norton RS; Chandy KG
    J Biol Chem; 1998 Dec; 273(49):32697-707. PubMed ID: 9830012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.
    Lanigan MD; Kalman K; Lefievre Y; Pennington MW; Chandy KG; Norton RS
    Biochemistry; 2002 Oct; 41(40):11963-71. PubMed ID: 12356296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
    Pennington MW; Lanigan MD; Kalman K; Mahnir VM; Rauer H; McVaugh CT; Behm D; Donaldson D; Chandy KG; Kem WR; Norton RS
    Biochemistry; 1999 Nov; 38(44):14549-58. PubMed ID: 10545177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
    Rauer H; Pennington M; Cahalan M; Chandy KG
    J Biol Chem; 1999 Jul; 274(31):21885-92. PubMed ID: 10419508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
    Norton RS; Pennington MW; Wulff H
    Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designed peptide analogues of the potassium channel blocker ShK toxin.
    Lanigan MD; Pennington MW; Lefievre Y; Rauer H; Norton RS
    Biochemistry; 2001 Dec; 40(51):15528-37. PubMed ID: 11747428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
    Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
    FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
    Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
    Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
    Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
    J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of the sea anemone toxin ShK recognizing the Kv1.3 channel explored by docking and molecular dynamic simulations.
    Jin L; Wu Y
    J Chem Inf Model; 2007; 47(5):1967-72. PubMed ID: 17718553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
    Beeton C; Wulff H; Singh S; Botsko S; Crossley G; Gutman GA; Cahalan MD; Pennington M; Chandy KG
    J Biol Chem; 2003 Mar; 278(11):9928-37. PubMed ID: 12511563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
    Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.
    Middleton RE; Sanchez M; Linde AR; Bugianesi RM; Dai G; Felix JP; Koprak SL; Staruch MJ; Bruguera M; Cox R; Ghosh A; Hwang J; Jones S; Kohler M; Slaughter RS; McManus OB; Kaczorowski GJ; Garcia ML
    Biochemistry; 2003 Nov; 42(46):13698-707. PubMed ID: 14622016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
    Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
    Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
    Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
    FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
    Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
    Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
    Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
    J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
    Pennington MW; Harunur Rashid M; Tajhya RB; Beeton C; Kuyucak S; Norton RS
    FEBS Lett; 2012 Nov; 586(22):3996-4001. PubMed ID: 23063513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
    Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
    Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.
    Pennington MW; Mahnir VM; Krafte DS; Zaydenberg I; Byrnes ME; Khaytin I; Crowley K; Kem WR
    Biochem Biophys Res Commun; 1996 Feb; 219(3):696-701. PubMed ID: 8645244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.